Following the success of last year's US Healthcare and Life Sciences Conference, the Financial Times, in association with Deloitte, hosted the second annual conference at the Metropolitan Club in New York on June 6, 2013.
The conference built on some of last year's themes and also focused on the practicalities of dealing with the provisions and impacts of US healthcare reform-taking its core theme as "Transformation Beyond Healthcare Reform". There is real appetite to know what the establishment of new institutions such as Accountable Care Organisations (ACOs) will mean for the future prospects for life science companies - are they a threat or an opportunity - and how changes in the payer/healthcare industry landscape, and their growing emphasis on the value they provide rather than products, might impact the industry's future profitability.
The conference also focused on other topical themes such as:
New models for financing R&D
Opportunities in emerging markets beyond the BRIC countries as the next range of countries start to attract the attention of life science companies
Challenges and opportunities represented by the increasing convergence between pharmacy diagnostic and devices companies and products
The FT US Healthcare and Life Sciences Conference brought together a distinguished line-up of industry experts, government decision-makers and leading market commentators to review the shifting sands of the US healthcare industry, and explore direct and indirect implications of reform for key stakeholders-payers, life science companies, healthcare providers, investors and patients.
To view video footage from the 2012 conference, please click here.
Confirmed Speakers Include
Pharmaceuticals Correspondent Financial Times
Ian Read, Chairman of the Board and CEO, Pfizer
David Meeker, MD, President, CEO, Genzyme
Jeff George, Global Head, Sandoz and Executive Committee Member, Novartis Tom Pike, CEO, Quintiles
Jan Groen, PhD, CEO, MDxHealth Jan Lundberg, PhD, Executive Vice President,Science and Technology and President, Lilly Research Laboratories John Noseworthy, MD, President and CEO, Mayo Clinic Jonathan Sheffield, CEO, NIHR Clinical Research Network John Capek, PhD, Executive Vice President, Medical Devices, Abbott Reynold (Pete) Mooney, Global Leader, Life Sciences and Health Care, Deloitte Touche Tohmatsu Terry Hisey, Vice Chairman, US Life Sciences Leader, Deloitte Fred Hassan, Managing Director, Healthcare, Warburg Pincus Paul Hudson, EVP, North America, AstraZeneca Scott Bruder, MD, PhD, Chief Medical and Scientific Officer, Stryker Amy Schulman, EVP and General Counsel; Business Unit Lead, Consumer Healthcare, Pfizer Arthur Higgins, Senior Consultant, Blackstone Healthcare Partners Colin Hill, CEO and Co-Founder, GNS Healthcare Michael Warmuth, EVP, Established Pharmaceuticals, Abbott